Biopharmaceutical Company Reports Strong Clinical Momentum For CTCL Treatment

Soligenix, Inc. (NASDAQ: SNGX), a late-stage biopharmaceutical company, has been making progress in the treatment of Cutaneous T-Cell Lymphoma (CTCL) with its investigational drug, HyBryte™. In an exclusive interview with PCG Digital, Dr. Brian Poligone, Director of the Rochester Skin Lymphoma Medical Group and Principal Investigator for Soligenix’s comparative study, sheds light on the promising advancements in this treatment area. $Soligenix (SNGX.US)$